Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Trisha Wise-Draper

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Laryngoscope Investigative Otolaryngology|April 18, 2022
A phase I/II trial of concurrent immunotherapy with chemoradiation in locally advanced larynx cancerAndrew J Frankart, Nooshin Hashemi Sadraei, Brad Huth, et al.
Cancer Chemotherapy and Pharmacology|July 2, 2023
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumorsMats Någård, Mei-Lin Ah-See, James Strauss, et al.
Translational Oncology|January 1, 2018
Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Case-Control Study of Patients with Head and Neck Squamous Cell CarcinomaTrisha Wise-Draper, Arun Sendilnathan, Sarah Palackdharry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2022
Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck CancerAlexander Y Deneka, Yasmine Baca, Ilya G Serebriiskii, et al.
Cancer Chemotherapy and Pharmacology|June 27, 2023
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label studyMats Någård, Mei-Lin Ah-See, James Strauss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2026
A Phase 2 Feasibility Study Combining Pembrolizumab and Metformin in patients with Metastatic Head and Neck CancerOlga Zamulko, Sam Nusbaum, Andrew Osterburg, et al.
Oral Oncology|February 11, 2021
Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trialDouglas R Adkins, Jin-Ching Lin, Assuntina Sacco, et al.
Frontiers in Oncology|December 13, 2021
Multi-Institutional Study Validates Safety of Intraoperative Cesium-131 Brachytherapy for Treatment of Recurrent Head and Neck CancerAdam Luginbuhl, Alyssa Calder, David Kutler, et al.
Cancer Cell|November 22, 2024
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activationDavid Hsiehchen, Andrew Elliott, Joanne Xiu, et al.
Clinical Therapeutics|February 29, 2024
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid TumorsGerald Falchook, Amita Patnaik, Debra L Richardson, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Laryngoscope Investigative Otolaryngology|April 18, 2022
A phase I/II trial of concurrent immunotherapy with chemoradiation in locally advanced larynx cancerAndrew J Frankart, Nooshin Hashemi Sadraei, Brad Huth, et al.
Cancer Chemotherapy and Pharmacology|July 2, 2023
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumorsMats Någård, Mei-Lin Ah-See, James Strauss, et al.
Translational Oncology|January 1, 2018
Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Case-Control Study of Patients with Head and Neck Squamous Cell CarcinomaTrisha Wise-Draper, Arun Sendilnathan, Sarah Palackdharry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2022
Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck CancerAlexander Y Deneka, Yasmine Baca, Ilya G Serebriiskii, et al.
Cancer Chemotherapy and Pharmacology|June 27, 2023
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label studyMats Någård, Mei-Lin Ah-See, James Strauss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2026
A Phase 2 Feasibility Study Combining Pembrolizumab and Metformin in patients with Metastatic Head and Neck CancerOlga Zamulko, Sam Nusbaum, Andrew Osterburg, et al.
Oral Oncology|February 11, 2021
Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trialDouglas R Adkins, Jin-Ching Lin, Assuntina Sacco, et al.
Frontiers in Oncology|December 13, 2021
Multi-Institutional Study Validates Safety of Intraoperative Cesium-131 Brachytherapy for Treatment of Recurrent Head and Neck CancerAdam Luginbuhl, Alyssa Calder, David Kutler, et al.
Cancer Cell|November 22, 2024
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activationDavid Hsiehchen, Andrew Elliott, Joanne Xiu, et al.
Clinical Therapeutics|February 29, 2024
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid TumorsGerald Falchook, Amita Patnaik, Debra L Richardson, et al.
Pageof 4